Tesamorelin
⥠Quick Description & Benefits
Brand name - EGRIFTA. Developed to treat HIV lipodystrophy. Human growth hormone-releasing hormone (GHRH).
Key Benefits:
- â Reduce triglycerides, liver and visceral fat
- â Decrease middle fat
- â Improve bone mineral density
- â Supports muscle metabolism
- â Benefits cardiovascular health
- â Can improve cognitive function
- â Depending on the needs, may be better than CJC-1295
ðŽ Detailed Function & Research
Mechanism & Function
Brand name - EGRIFTA. Developed to treat HIV lipodystrophy. Human growth hormone-releasing hormone (GHRH). It operates by stimulating specific cellular receptors, activating downstream enzymatic pathways and physiological repair mechanisms without widespread systemic disturbance.
Research & Scientific Support
Extensive pre-clinical and translational models demonstrate consistent receptor affinity and regenerative signalling across controlled studies.
Protocol Notes:
- âĒ Human growth hormone-releasing hormone (GHRH)
- âĒ GHRH should be paired with GHRP
- âĒ Brand name - EGRIFTA
- âĒ Developed to treat HIV lipodystrophy
ð§Ū Dosing & Reconstitution Calculator
Calculate syringe units or suggest optimal reconstitution solution volume
Volume Guideline: Most subcutaneous injections should fall between 10 and 20 units for optimal comfort, though certain peptides may feel better at volumes up to 60 units. Increments start at 1.0ml in 0.5ml steps.
ð Research Papers & Clinical Studies
Peer-reviewed research and indexed publications for Tesamorelin:
ð Dosing & Administration
FDA-approved for HIV lipodystrophy, potent visceral fat reduction
ð Pairs Well With
â ïļ Side Effects
- ! ISR
- ! Difficulty breathing
- ! Dizziness
- ! Elevations in blood sugar levels
- ! Fast heartbeat
- ! Hives
- ! Joint pain
- ! Night sweats
- ! Numbness
- ! Rash
- ! Vomiting